SFT — Sopharma Trading AD Income Statement
0.000.00%
- BGN194.76m
- BGN476.93m
- BGN1.96bn
- 68
- 99
- 70
- 95
Annual income statement for Sopharma Trading AD, fiscal year end - December 31st, BGN millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,165 | 1,344 | 1,487 | 1,681 | 1,956 |
| Cost of Revenue | |||||
| Gross Profit | 99.9 | 133 | 159 | 175 | 223 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1,148 | 1,330 | 1,469 | 1,636 | 1,895 |
| Operating Profit | 17.7 | 13.8 | 18.3 | 44.6 | 61.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 13.9 | 9.44 | 12.4 | 34.2 | 47 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 11.5 | 8.05 | 9.08 | 29.2 | 39.8 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 11.5 | 8.05 | 9.08 | 29.2 | 40.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 11.5 | 8.05 | 9.08 | 29.2 | 40.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.335 | 0.235 | 0.737 | 0.862 | 1.19 |
| Dividends per Share |